Top

Published in:

01-05-2020 | Editorial

The MASCC/ISOO mucositis guidelines 2019: the second set of articles and future directions

Author: Sharon Elad

Published in: Supportive Care in Cancer | Issue 5/2020

Excerpt

This editorial introduces the second set of articles related to the update of the clinical practice guidelines for mucositis, developed by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). The first set of articles was published in a special section of the July 2019 issue of Supportive Care in Cancer. The July 2019 articles described the methods used [1] and results related to gastrointestinal mucositis [2], as well as other classes of interventions for oral mucositis including anti-inflammatory agents [3], photobiomodulation [4], vitamins, minerals, and nutritional supplements [5], and protocols categorized as basic oral care [6]. Furthermore, an entire paper was dedicated to advances in the understanding of the pathogenesis of mucositis [7]. …

Ranna V, Cheng KKF, Castillo DA, Porcello L, Vaddi A, Lalla RV, Bossi P, Elad S (2019) Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods. Support Care Cancer 27:3933–3948CrossRef

Bowen JM, Gibson RJ, Coller JK, Blijlevens N, Bossi P, Al-Dasooqi N, Bateman EH, Chiang K, de Mooij C, Mayo B, Stringer AM, Tissing W, Wardill HR, van Sebille YZA, Ranna V, Vaddi A, Keefe DM, Lalla RV, Cheng KKF, Elad S (2019) Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. Support Care Cancer 27:4011–4022CrossRef

Ariyawardana A, Cheng KKF, Kandwal A, Tilly V, Al-Azri AR, Galiti D, Chiang K, Vaddi A, Ranna V, Nicolatou-Galitis O, Lalla RV, Bossi P, Elad S (2019) Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer 27:3985–3995CrossRef

Zadik Y, Arany PR, Fregnani ER, Bossi P, Antunes HS, Bensadoun RJ, Gueiros LA, Majorana A, Nair RG, Ranna V, Tissing WJE, Vaddi A, Lubart R, Migliorati CA, Lalla RV, Cheng KKF, Elad S (2019) Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer 27:3969–3983CrossRef

Yarom N, Hovan A, Bossi P, Ariyawardana A, Jensen SB, Gobbo M, Saca-Hazboun H, Kandwal A, Majorana A, Ottaviani G, Pentenero M, Nasr NM, Rouleau T, Lucas AS, Treister NS, Zur E, Ranna V, Vaddi A, Cheng KKF, Barasch A, Lalla RV, Elad S (2019) Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines-part 1: vitamins, minerals, and nutritional supplements. Support Care Cancer 27:3997–4010CrossRef

Hong CHL, Gueiros LA, Fulton JS, Cheng KKF, Kandwal A, Galiti D, Fall-Dickson JM, Johansen J, Ameringer S, Kataoka T, Weikel D, Eilers J, Ranna V, Vaddi A, Lalla RV, Bossi P, Elad S (2019) Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer 27:3949–3967CrossRef

Bowen J, Al-Dasooqi N, Bossi P, Wardill H, Van Sebille Y, Al-Azri A, Bateman E, Correa ME, Raber-Durlacher J, Kandwal A, Mayo B, Nair RG, Stringer A, Ten Bohmer K, Thorpe D, Lalla RV, Sonis S, Cheng KKF, Elad S (2019) The pathogenesis of mucositis: updated perspectives and emerging targets. Support Care Cancer 27:4023–4033CrossRef

Logan RM, Al-Azri AR, Bossi P, Stringer AM, Joy JK, Soga Y, Ranna V, Vaddi A, Raber-Durlacher J, Lalla RV, Cheng KKF, Elad S (2019) Systematic review of growth factors and cytokines for the management of Oral Mucositis in cancer patients and clinical practice guidelines. Support Care Cancer https://doi.org/10.1007/s00520-019-05170-9 CrossRef

Saunders DP, Rouleau T, Cheng KKF, Yarom N, Kandwal A, Joy J, Bektas K, van de Wetering M, Brito-Dellan N, Kataoka T, Chiang K, Ranna V, Vaddi A, Epstein J, Lalla RV, Bossi P, Elad S (2019) Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer https://doi.org/10.1007/s00520-019-05181-6 CrossRef

10.

Correa MEP, Cheng KKF, Chiang K, Kandwal A, Loprinzi CL, Mori T, Potting C, Rouleau T, Toro JJ, Ranna V, Vaddi A, Peterson DE, Bossi P, Lalla RV, Elad S (2019) Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer https://doi.org/10.1007/s00520-019-05217-x CrossRef

11.

Yarom N, Hovan A, Bossi P, Ariyawardana A, Jensen SB, Gobbo M, Hazboun HI, Kandwal A, Majorana A, Ottaviani G, Pentenero M, Nasr N, Rouleau T, Skripnik Lucas A, Treister NS, Zur E, Ranna V, Vaddi A, Cheng KKF, Barasch A, Lalla RV, Elad S (2019) Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines – Part 2: honey, herbal compounds, saliva stimulants/inhibitors, probiotics and miscellaneous agents. Support Care Cancer https://doi.org/10.1007/s00520-019-05256-4 CrossRef

12.

Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120:1453–1461CrossRef

13.

Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026–2046CrossRef

14.

Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831CrossRef

15.

Bowen JM, Elad S, Hutchins RD, Lalla RV (2013) Methodology for the MASCC/ISOO Mucositis clinical practice guidelines update. Support Care Cancer 21:303–308CrossRef

16.

Elad S, Bowen J, Zadik Y, Lalla RV (2013) Development of the MASCC/ISOO clinical practice guidelines for mucositis: considerations underlying the process. Support Care Cancer 21:309–312CrossRef

17.

Hadorn DC, Baker D, Hodges JS, Hicks N (1996) Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 49:749–754CrossRef

18.

Somerfield MR, McCrae RR (2000) Stress and coping research. Methodological challenges, theoretical advances, and clinical applications. Am Psychol 55:620–625CrossRef

Title: The MASCC/ISOO mucositis guidelines 2019: the second set of articles and future directions
Author: Sharon Elad
Publication date: 01-05-2020
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 5/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-05153-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2020

Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide

Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study

Preoperative rehabilitation for patients undergoing colorectal cancer surgery: a retrospective cohort study

Questioning the acute effect of orange chromatic environment on perceived health status, pain, and vital signs during chemotherapy treatment

Adherence to and satisfaction with low-intensity physical activity and supervised moderate-high intensity exercise during chemotherapy for breast cancer

Acute effect of orange chromatic environment on perceived health status, pain, and vital signs during chemotherapy treatment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer